Please login to the form below

Not currently logged in
Email:
Password:

antibody-drug conjugates

This page shows the latest antibody-drug conjugates news and features for those working in and with pharma, biotech and healthcare.

Bayer gets clinical data to support $1.5bn Loxo deal

Bayer gets clinical data to support $1.5bn Loxo deal

In all but one cases the 17 patients have remained on drug therapy or received surgery with the intent of curing the cancer, according to the investigators. ... stage projects in oncogenic signalling, antibody-drug conjugates, targeted thorium conjugates

Latest news

More from news
Approximately 7 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    The antibody, to be known as COR-001, will be progressed for cardiovascular applications. ... This month saw two existing partnerships that have been extended. Takeda has been working with Mersana Therapeutics since 2014 to develop antibody drug

  • Pharma deals in April 2015 Pharma deals in April 2015

    The agreement also includes payment of double digit royalties. Innate also put in place a collaboration with Sanofi for next generation antibody-drug conjugates (ADCs) using Innate's site specific conjugation ... its SAR3419, an antibody-drug conjugate

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 150. Sutro Biopharma/Celgene. Licence plus option to acquire Sutro. For development of multispecific antibodies and antibody drug conjugates (ADCs). ... 475. CureTech/Medivation. Exclusive global licence. For pidilizumab (CT-011), an immune modulatory

  • Pharma deals during October 2014 Pharma deals during October 2014

    An oncology deal for multispecific antibodies and antibody drug conjugates [ADCs], this transaction builds on the original deal signed in December 2012 with a headline of $500m. ... Keeping it flexible, Roche extended its 2013 licence agreement with

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    68. Sorrento Therapeutics / Morphotek. Research and option agreement. To generate chemotherapeutic antibody drug conjugates (ADCs) (platform).

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics. ... We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics expands team. Appointments preceed its first antibody drug conjugate trials. ... ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... Both positions will be crucial to supporting the San Francisco-based biotech's growth following CytomX's  $635m deal agreed with

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics